Correlation Engine 2.0
Clear Search sequence regions


  • endotoxemia (6)
  • Gal3 (12)
  • Gal3 (1)
  • knockout mice (2)
  • macrophages (1)
  • mice (2)
  • monocytes (1)
  • sepsis (2)
  • serum (1)
  • Sizes of these terms reflect their relevance to your search.

    Lipopolysaccharide (LPS)-induced endotoxemia induces an acute systemic inflammatory response that mimics some important features of sepsis, the disease with the highest mortality rate worldwide. In this work, we have analyzed a murine model of endotoxemia based on a single intraperitoneal injection of 5 mg/kg of LPS. We took advantage of galectin-3 (Gal3) knockout mice and found that the absence of Gal3 decreased the mortality rate oflethal endotoxemia in the first 80 h after the administration of LPS, along with a reduction in the tissular damage in several organs measured by electron microscopy. Using flow cytometry, we demonstrated that, in control conditions, peripheral immune cells, especially monocytes, exhibited high levels of Gal3, which were early depleted in response to LPS injection, thus suggesting Gal3 release under endotoxemia conditions. However, serum levels of Gal3 early decreased in response to LPS challenge (1 h), an indication that Gal3 may be extravasated to peripheral organs. Indeed, analysis of Gal3 in peripheral organs revealed a robust up-regulation of Gal3 36 h after LPS injection. Taken together, these results demonstrate the important role that Gal3 could play in the development of systemic inflammation, a well-established feature of sepsis, thus opening new and promising therapeutic options for these harmful conditions.

    Citation

    Juan Carlos Fernández-Martín, Ana María Espinosa-Oliva, Irene García-Domínguez, Isaac Rosado-Sánchez, Yolanda M Pacheco, Rosario Moyano, José G Monterde, José Luis Venero, Rocío M de Pablos. Gal3 Plays a Deleterious Role in a Mouse Model of Endotoxemia. International journal of molecular sciences. 2022 Jan 21;23(3)

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 35163089

    View Full Text